Wednesday, July 8, 2026

pharma · Acute Myeloid Leukemia · Acute Leukemia · ATNM

Actinium Pharmaceuticals

Actinium Pharmaceuticals clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

New York, USA HQ
2000 Founded
58 Employees
Public company Type
ATNM · NYSE Ticker
Company details
Status
Public
HQ
New York, USA
Founded
2000
Employees
58
Programs
8
Drugs
4
Patents
20
Intelligence · Clinical Programs

Actinium Pharmaceuticals projects

3 ClinicalTrials.gov programs sponsored by Actinium Pharmaceuticals.

Actinium Pharmaceuticals has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Cytarabine (Phase 1 only)

    Actinium Pharmaceuticals

    AML

    phase 2 small molecule completed

    1 trial
  2. Iomab-B

    Actinium Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial
  3. Lintuzumab-Ac225

    Actinium Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 mab active

    2 trials

Frequently asked questions

How many clinical projects does Actinium Pharmaceuticals have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.